Alterity Therapeutics Files 6-K on Director Interest Change
Ticker: PRNAF · Form: 6-K · Filed: Apr 29, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, director-change, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K for director interest changes; check filings for details.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on April 29, 2025, to report a change in a director's interest. This filing is incorporated by reference into several of the company's existing registration statements on Form S-8 and Form F-3.
Why It Matters
Changes in director interests can signal shifts in insider confidence or strategic adjustments within the company.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of director interest changes and does not indicate significant new risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Filer of the 6-K report
- April 29, 2025 (date) — Filing date of the 6-K
- Form S-8 (document) — Registration statement into which the 6-K is incorporated
- Form F-3 (document) — Registration statement into which the 6-K is incorporated
- Change of Director's Interest Notice (document) — Exhibit submitted with the 6-K
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a change in a director's interest and to incorporate this information by reference into existing registration statements.
When was this Form 6-K filed?
This Form 6-K was filed on April 29, 2025.
Which registration statements is this 6-K incorporated into?
This 6-K is incorporated into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What specific exhibit is included with this 6-K?
The specific exhibit included with this 6-K is '99.1 Change of Director’s Interest Notice x 3'.
What is the principal executive office address of Alterity Therapeutics?
The principal executive office address of Alterity Therapeutics is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).